RIVA-ZOLMITRIPTAN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ZOLMITRIPTAN

Pieejams no:

LABORATOIRE RIVA INC.

ATĶ kods:

N02CC03

SNN (starptautisko nepatentēto nosaukumu):

ZOLMITRIPTAN

Deva:

2.5MG

Zāļu forma:

TABLET

Kompozīcija:

ZOLMITRIPTAN 2.5MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

6/30

Receptes veids:

Prescription

Ārstniecības joma:

SELECTIVE SEROTONIN AGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0134381001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2019-03-05

Produkta apraksts

PRODUCT MONOGRAPH
PR
(ZOLMITRIPTAN FILM-COATED TABLETS)
RIVA-ZOLMITRIPTAN
2.5 MG
5-HT1 RECEPTOR AGONIST
MIGRAINE THERAPY
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Québec, Canada.
J7C 3V4
www.labriva.com
Date of Revision:
August 25, 2015
Submission Control #: 186807
_RIVA-ZOLMITRIPTAN Product Monograph _
_Page 2 of 36 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................17
DOSAGE AND ADMINISTRATION
..............................................................................19
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION ...............................................................................24
PHARMACEUTICAL INFORMATION
..........................................................................24
CLINICAL TRIALS
..........................................................................................................25
DETAILED PHARMACOLOGY
......................